|
業務類別
|
Biotechnology |
|
業務概覽
|
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders. |
| 公司地址
| 125 Strafford Avenue, Suite 360, Wayne, PA, USA, 19087 |
| 電話號碼
| +1 484 253-1461 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.palvellatx.com |
| 員工數量
| 14 |
| Mr. Wesley H. Kaupinen |
Chief Executive Officer, President and Director |
美元 384.92K |
30/04/2025 |
| Mr. Matthew E. Korenberg |
Secretary, Principal Accounting Officer, Chief Financial Officer and Treasurer |
-- |
30/04/2025 |
| Ms. Kathleen Goin |
Chief Operating Officer |
美元 381.44K |
30/04/2025 |
| Mr. Jeffrey Martini, PhD |
Chief Scientific Officer |
美元 320.76K |
30/04/2025 |
|
|
| Mr. Wesley H. Kaupinen |
Chief Executive Officer, President and Director |
30/04/2025 |
| Dr. Elaine J. Heron, M.B.A.,PhD |
Independent Director |
30/04/2025 |
| Mr. Tadd S. Wessel |
Independent Director |
30/04/2025 |
| Mr. Christopher Kiritsy |
Independent Director |
30/04/2025 |
| Mr. George M. Jenkins |
Chairman of the Board |
30/04/2025 |
| Mr. Todd C. Davis |
Independent Director |
30/04/2025 |
|
|
|
|
